8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 4, 2026·SEC
Material company update
Nov 21, 2025·SEC
Eli Lilly and Company(LLY)Earnings, Financials & Key Ratios
LLY•NYSE
47.8× P/E·Price updated Jun 19, 2026
AboutEli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.Show more
- Revenue$65.18B+44.7%
- EBITDA$31.26B+62.2%
- Net Income$20.64B+94.9%
- EPS (Diluted)22.95+96.0%
- Gross Margin83.79%+3.1%
- EBITDA Margin47.96%+12.1%
- Operating Margin45.56%+17.3%
- Net Margin31.66%+34.7%
- ROE101.15%+20.0%
LLY Key Insights
Eli Lilly and Company (LLY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 78.0%
- ✓Strong 5Y profit CAGR of 27.2%
- ✓Strong Piotroski F-Score: 8/9
- ✓11 consecutive years of dividend growth
- ✓Strong 5Y sales CAGR of 21.6%
- ✓Healthy 5Y average net margin of 22.4%
✗Weaknesses
- ✗Expensive at 37.2x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LLY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LLY Price & Volume
Eli Lilly and Company (LLY) stock price & volume — 10-year historical chart
Loading chart...
LLY Growth Metrics
Eli Lilly and Company (LLY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years12.56%
5 Years21.58%
3 Years31.69%
TTM47.44%
Profit CAGR
10 Years23.96%
5 Years27.22%
3 Years48.95%
TTM127.57%
EPS CAGR
10 Years26.54%
5 Years28.82%
3 Years51.73%
TTM129.05%
Return on Capital
10 Years25.9%
5 Years33.51%
3 Years39.33%
Last Year46.55%
LLY Recent Earnings
Eli Lilly and Company (LLY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 9/12 qtrs (82%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$8.55+22.7%
$6.97
Rev
$19.8B+11.1%
$17.8B
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$7.54+9.1%
$6.91
Rev
$19.3B+7.5%
$17.9B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$7.02+23.4%
$5.69
Rev
$17.6B+9.6%
$16.1B
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$6.31+12.7%
$5.60
Rev
$15.6B+5.8%
$14.7B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $8.55vs $6.97+22.7% | $19.8Bvs $17.8B+11.1% |
| Q1 2026 | Feb 4, 2026 | $7.54vs $6.91+9.1% | $19.3Bvs $17.9B+7.5% |
| Q4 2025 | Oct 30, 2025 | $7.02vs $5.69+23.4% | $17.6Bvs $16.1B+9.6% |
| Q3 2025 | Aug 7, 2025 | $6.31vs $5.60+12.7% | $15.6Bvs $14.7B+5.8% |
Based on last 12 quarters of dataView full earnings history →
LLY Peer Comparison
Eli Lilly and Company (LLY) competitors in Large diversified branded pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 AZN | 271.19B | 174.93 | 26.75 | 8.63% | 17.19% | 22.24% | 0.61 | |
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 JNJ | 550.4B | 228.39 | 39.45 | 4.3% | 27.26% | 31.69% | 0.51 | |
 NVS | 280.64B | 147.08 | 20.46 | 5.97% | 24.14% | 31.42% | 0.80 |
Compare LLY vs Peers
Eli Lilly and Company (LLY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LLY Income Statement
Eli Lilly and Company (LLY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 19.97B | 21.49B | 22.32B | 24.54B | 28.32B | 28.54B | 34.12B | 45.04B | 65.18B | 72.25B |
Revenue Growth % | -5.88% | 7.61% | 3.84% | 9.95% | 15.4% | 0.79% | 19.56% | 32% | 44.7% | 47.44% |
Cost of Goods Sold | 4.45B | 4.68B | 4.72B | 5.48B | 7.31B | 6.63B | 7.08B | 8.42B | 10.56B | 11.92B |
COGS % of Revenue | 22.27% | 21.78% | 21.15% | 22.34% | 25.82% | 23.23% | 20.75% | 18.69% | 16.21% | - |
Gross Profit | 15.53B▲ 0% | 16.81B▲ 8.3% | 17.6B▲ 4.7% | 19.06B▲ 8.3% | 21.01B▲ 10.2% | 21.91B▲ 4.3% | 27.04B▲ 23.4% | 36.62B▲ 35.4% | 54.62B▲ 49.1% | 60.33B▲ 0% |
Gross Margin % | 77.73% | 78.22% | 78.85% | 77.66% | 74.18% | 76.77% | 79.25% | 81.31% | 83.79% | 83.51% |
Gross Profit Growth % | 0.09% | 8.28% | 4.68% | 8.29% | 10.23% | 4.31% | 23.41% | 35.44% | 49.12% | - |
Operating Expenses | 11.28B | 10.79B | 11.6B | 11.85B | 13.07B | 13.26B | 16.25B | 19.12B | 24.92B | 27.2B |
OpEx % of Revenue | 56.46% | 50.18% | 51.97% | 48.27% | 46.16% | 46.45% | 47.63% | 42.45% | 38.23% | - |
Selling, General & Admin | 6.18B | 5.73B | 6B | 5.87B | 6.14B | 6.07B | 6.94B | 8.13B | 11.09B | 11.67B |
SG&A % of Revenue | 30.94% | 26.68% | 26.9% | 23.92% | 21.69% | 21.26% | 20.34% | 18.05% | 17.02% | - |
Research & Development | 5.1B | 5.05B | 5.59B | 5.98B | 6.93B | 7.19B | 9.31B | 10.99B | 13.34B | 14.11B |
R&D % of Revenue | 25.51% | 23.5% | 25.07% | 24.35% | 24.47% | 25.19% | 27.29% | 24.4% | 20.46% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 487.5M | 2M |
Operating Income | 4.25B▲ 0% | 6.03B▲ 41.8% | 6B▼ 0.4% | 7.21B▲ 20.2% | 7.93B▲ 10.0% | 8.65B▲ 9.1% | 10.79B▲ 24.7% | 17.5B▲ 62.2% | 29.7B▲ 69.7% | 33.14B▲ 0% |
Operating Margin % | 21.28% | 28.04% | 26.88% | 29.38% | 28.01% | 30.32% | 31.61% | 38.86% | 45.56% | 45.87% |
Operating Income Growth % | 9.78% | 41.79% | -0.44% | 20.19% | 10.02% | 9.08% | 24.66% | 62.24% | 69.67% | - |
EBITDA | 5.82B | 7.63B | 7.23B | 8.53B | 9.48B | 10.18B | 12.31B | 19.27B | 31.26B | 34.75B |
EBITDA Margin % | 29.12% | 35.52% | 32.4% | 34.78% | 33.48% | 35.65% | 36.09% | 42.78% | 47.96% | 48.09% |
EBITDA Growth % | 8.37% | 31.25% | -5.28% | 18.01% | 11.08% | 7.33% | 21.02% | 56.47% | 62.23% | 57.92% |
D&A (Non-Cash Add-back) | 1.57B | 1.61B | 1.23B | 1.32B | 1.55B | 1.52B | 1.53B | 1.77B | 1.56B | 1.61B |
EBIT | 2.53B | 3.92B | 5.67B | 7.59B | 6.5B | 7.14B | 7.04B | 13.46B | 26.37B | 31.52B |
Net Interest Income | -58.6M | -83.2M | -320.2M | -326.6M | -314.4M | -268.8M | -312.3M | -605.4M | -642M | -778.6M |
Interest Income | 166.4M | 159.3M | 80.4M | 33M | 25.4M | 62.8M | 173.6M | 175.2M | 153.3M | 105M |
Interest Expense | 225M | 242.5M | 400.6M | 359.6M | 339.8M | 331.6M | 485.9M | 780.6M | 795.3M | 883.6M |
Other Income/Expense | -1.95B | -2.35B | -733.5M | 19.1M | -1.78B | -1.85B | -4.23B | -4.82B | -3.96B | -2.01B |
Pretax Income | 2.3B▲ 0% | 3.68B▲ 59.7% | 5.27B▲ 43.1% | 7.23B▲ 37.3% | 6.16B▼ 14.9% | 6.81B▲ 10.6% | 6.55B▼ 3.7% | 12.68B▲ 93.5% | 25.73B▲ 102.9% | 31.12B▲ 0% |
Pretax Margin % | 11.54% | 17.12% | 23.59% | 29.46% | 21.74% | 23.85% | 19.21% | 28.15% | 39.48% | 43.08% |
Income Tax | 2.39B | 529.5M | 628M | 1.04B | 573.8M | 561.6M | 1.31B | 2.09B | 5.09B | 5.85B |
Effective Tax Rate % | 103.75% | 14.39% | 11.93% | 14.33% | 9.32% | 8.25% | 20.05% | 16.49% | 19.79% | 18.79% |
Net Income | -204.1M▲ 0% | 3.23B▲ 1683.5% | 8.32B▲ 157.4% | 6.19B▼ 25.5% | 5.58B▼ 9.9% | 6.24B▲ 11.9% | 5.24B▼ 16.1% | 10.59B▲ 102.1% | 20.64B▲ 94.9% | 25.27B▲ 0% |
Net Margin % | -1.02% | 15.04% | 37.27% | 25.24% | 19.71% | 21.88% | 15.36% | 23.51% | 31.66% | 34.98% |
Net Income Growth % | -107.46% | 1683.54% | 157.38% | -25.54% | -9.88% | 11.88% | -16.08% | 102.08% | 94.88% | 127.57% |
Net Income (Continuing) | -86.4M | 3.15B | 4.64B | 6.19B | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B | 25.27B |
Discontinued Operations | -117.7M | 81.4M | 3.68B | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 75.7M | 1.08B | 92.2M | 183.6M | 175.6M | 125.6M | 91.8M | 79.5M | 0 | 0 |
EPS (Diluted) | -0.19▲ 0% | 3.13▲ 1747.4% | 8.69▲ 177.6% | 6.47▼ 25.5% | 5.85▼ 9.6% | 6.57▲ 12.3% | 5.80▼ 11.7% | 11.71▲ 101.9% | 22.95▲ 96.0% | 28.21▲ 0% |
EPS Growth % | -107.63% | 1747.37% | 177.64% | -25.55% | -9.58% | 12.31% | -11.72% | 101.9% | 95.99% | 129.05% |
EPS (Basic) | -0.19 | 3.14 | 8.69 | 6.47 | 5.85 | 6.57 | 5.83 | 11.76 | 23.00 | - |
Diluted Shares Outstanding | 1.05B | 1.03B | 957.53M | 956.59M | 953.65M | 950.18M | 903.28M | 904.06M | 898M | 895.9M |
Basic Shares Outstanding | 1.05B | 1.03B | 957.53M | 956.59M | 953.65M | 950.18M | 899.38M | 900.61M | 898M | 894.5M |
Dividend Payout Ratio | - | 71.53% | 28.97% | 43.38% | 55.3% | 56.62% | 77.65% | 44.2% | 26.09% | - |
LLY Balance Sheet
Eli Lilly and Company (LLY) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 19.2B | 20.55B | 13.71B | 17.46B | 18.45B | 18.03B | 25.73B | 32.74B | 55.63B | 54.84B |
Cash & Short-Term Investments | 8.03B | 7.41B | 2.44B | 3.68B | 3.91B | 2.21B | 2.93B | 3.42B | 7.27B | 5.28B |
Cash Only | 6.54B | 7.32B | 2.34B | 3.66B | 3.82B | 2.07B | 2.82B | 3.27B | 7.16B | 5.28B |
Short-Term Investments | 1.5B | 88.2M | 101M | 24.2M | 90.1M | 144.8M | 109.1M | 154.8M | 105M | 0 |
Accounts Receivable | 5.26B | 5.78B | 5.54B | 6.93B | 8.13B | 8.56B | 11.34B | 13.28B | 20.16B | 21.18B |
Days Sales Outstanding | 96.16 | 98.1 | 90.62 | 103.06 | 104.75 | 109.45 | 121.25 | 107.58 | 112.87 | 98.51 |
Inventory | 4.46B | 3.1B | 3.19B | 3.98B | 3.89B | 4.31B | 5.77B | 7.59B | 13.74B | 14.53B |
Days Inventory Outstanding | 365.87 | 241.54 | 246.68 | 264.95 | 193.96 | 237.27 | 297.52 | 329.05 | 474.87 | 394.1 |
Other Current Assets | 0 | 2.23B | 0 | 0 | 0 | 7.3M | 149.5M | 111.4M | 147M | 13.85B |
Total Non-Current Assets | 25.78B | 23.36B | 25.58B | 29.17B | 30.35B | 31.46B | 38.28B | 45.98B | 56.85B | 61.74B |
Property, Plant & Equipment | 8.83B | 8B | 8.4B | 8.68B | 8.99B | 10.14B | 12.91B | 17.1B | 24.68B | 26.54B |
Fixed Asset Turnover | 2.26x | 2.69x | 2.66x | 2.83x | 3.15x | 2.81x | 2.64x | 2.63x | 2.64x | 3.07x |
Goodwill | 4.37B | 1.37B | 3.68B | 3.77B | 3.89B | 4.07B | 4.94B | 5.77B | 5.9B | 6.13B |
Intangible Assets | 4.03B | 1.07B | 6.62B | 7.45B | 7.69B | 7.21B | 6.91B | 6.17B | 6.52B | 7.37B |
Long-Term Investments | 5.68B | 2.02B | 1.96B | 2.97B | 3.21B | 2.9B | 3.05B | 3.22B | 2.8B | 11.93B |
Other Non-Current Assets | 2.87B | 8.3B | 2.34B | 3.48B | 4.08B | 4.34B | 4.99B | 5.72B | 6.99B | 7.23B |
Total Assets | 44.98B▲ 0% | 43.91B▼ 2.4% | 39.29B▼ 10.5% | 46.63B▲ 18.7% | 48.81B▲ 4.7% | 49.49B▲ 1.4% | 64.01B▲ 29.3% | 78.71B▲ 23.0% | 112.48B▲ 42.9% | 116.58B▲ 0% |
Asset Turnover | 0.44x | 0.49x | 0.57x | 0.53x | 0.58x | 0.58x | 0.53x | 0.57x | 0.58x | 0.65x |
Asset Growth % | 15.91% | -2.38% | -10.53% | 18.7% | 4.66% | 1.4% | 29.33% | 22.98% | 42.89% | 165.74% |
Total Current Liabilities | 14.54B | 11.89B | 11.78B | 12.48B | 15.05B | 17.14B | 27.29B | 28.38B | 35.23B | 36.63B |
Accounts Payable | 1.41B | 1.21B | 1.41B | 1.61B | 1.67B | 1.93B | 2.6B | 3.23B | 5.38B | 5.03B |
Days Payables Outstanding | 115.77 | 94.11 | 108.64 | 106.95 | 83.38 | 106.29 | 133.94 | 139.99 | 185.85 | 143.54 |
Short-Term Debt | 3.71B | 1.1B | 1.5B | 8.7M | 1.54B | 1.5B | 6.9B | 5.12B | 1.64B | 4B |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7.82B | 3.69B | 3.1B | 9.3B | 10.68B | 3.91B | 16.14B | 7.15B | 28.21B | 27.61B |
Current Ratio | 1.32x | 1.73x | 1.16x | 1.40x | 1.23x | 1.05x | 0.94x | 1.15x | 1.58x | 1.50x |
Quick Ratio | 1.01x | 1.47x | 0.89x | 1.08x | 0.97x | 0.80x | 0.73x | 0.89x | 1.19x | 1.10x |
Cash Conversion Cycle | 346.26 | 245.53 | 228.65 | 261.06 | 215.33 | 240.44 | 284.84 | 296.64 | 401.89 | 349.06 |
Total Non-Current Liabilities | 18.78B | 21.11B | 24.81B | 28.33B | 24.6B | 21.58B | 25.85B | 36.07B | 50.71B | 48.74B |
Long-Term Debt | 9.93B | 9.2B | 13.82B | 16.59B | 15.35B | 14.74B | 18.32B | 28.53B | 40.87B | 39.37B |
Capital Lease Obligations | 0 | 0 | 486.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 1.31B | 2.19B | 2.1B | 1.73B | 87.3M | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8.85B | 10.6B | 8.32B | 9.64B | 7.52B | 6.75B | 7.53B | 7.54B | 9.85B | 9.37B |
Total Liabilities | 33.31B | 33B | 36.59B | 40.81B | 39.65B | 38.71B | 53.14B | 64.44B | 85.94B | 85.38B |
Total Debt | 13.65B | 10.3B | 15.8B | 16.6B | 16.88B | 16.24B | 25.23B | 33.64B | 42.5B | 43.37B |
Net Debt | 7.11B | 2.98B | 13.47B | 12.94B | 13.07B | 14.17B | 22.41B | 30.38B | 35.34B | 38.09B |
Debt / Equity | 1.17x | 0.94x | 5.86x | 2.85x | 1.84x | 1.51x | 2.32x | 2.36x | 1.60x | 1.39x |
Debt / EBITDA | 2.35x | 1.35x | 2.19x | 1.94x | 1.78x | 1.60x | 2.05x | 1.75x | 1.36x | 1.25x |
Net Debt / EBITDA | 1.22x | 0.39x | 1.86x | 1.52x | 1.38x | 1.39x | 1.82x | 1.58x | 1.13x | 1.10x |
Interest Coverage | 11.24x | 16.18x | 14.15x | 21.11x | 19.12x | 21.53x | 14.49x | 17.24x | 33.16x | 35.68x |
Total Equity | 11.67B▲ 0% | 10.91B▼ 6.5% | 2.7B▼ 75.3% | 5.83B▲ 115.8% | 9.15B▲ 57.2% | 10.78B▲ 17.7% | 10.86B▲ 0.8% | 14.27B▲ 31.4% | 26.54B▲ 85.9% | 31.2B▲ 0% |
Equity Growth % | -17.13% | -6.5% | -75.26% | 115.82% | 57.16% | 17.7% | 0.82% | 31.37% | 85.93% | 283.92% |
Book Value per Share | 11.09 | 10.55 | 2.82 | 6.09 | 9.60 | 11.34 | 12.03 | 15.79 | 29.55 | 34.82 |
Total Shareholders' Equity | 11.59B | 9.83B | 2.61B | 5.64B | 8.98B | 10.65B | 10.77B | 14.19B | 26.54B | 31.2B |
Common Stock | 687.9M | 661M | 598.8M | 598.2M | 596.3M | 594.1M | 593.6M | 592.4M | 590M | 590M |
Retained Earnings | 13.89B | 11.4B | 4.92B | 7.83B | 8.96B | 10.04B | 10.31B | 13.54B | 24.47B | 29.51B |
Treasury Stock | -75.8M | -69.4M | -60.8M | -55.7M | -52.7M | -50.5M | -44.2M | -49.5M | 0 | 0 |
Accumulated OCI | -8.73B | -8.74B | -6.52B | -9.51B | -4.34B | -3.84B | -4.33B | -4.32B | -2.88B | -2.83B |
Minority Interest | 75.7M | 1.08B | 92.2M | 183.6M | 175.6M | 125.6M | 91.8M | 79.5M | 0 | 0 |
LLY Cash Flow Statement
Eli Lilly and Company (LLY) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 5.62B | 5.52B | 4.84B | 6.5B | 7.37B | 7.59B | 4.24B | 8.82B | 16.81B | 20.48B |
Operating CF Margin % | 28.11% | 25.7% | 21.67% | 26.49% | 26.01% | 26.58% | 12.43% | 19.58% | 25.8% | - |
Operating CF Growth % | 15.76% | -1.62% | -12.45% | 34.38% | 13.33% | 2.98% | -44.1% | 107.96% | 90.67% | 499.11% |
Net Income | -204.1M | 3.23B | 8.32B | 6.19B | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B | 25.27B |
Depreciation & Amortization | 1.57B | 1.61B | 1.23B | 1.32B | 1.55B | 1.52B | 1.53B | 1.77B | 2B | 2.04B |
Stock-Based Compensation | 281.3M | 279.5M | 312.4M | 308.1M | 342.8M | 371.1M | 628.5M | 645.6M | 626M | 633.3M |
Deferred Taxes | -787.9M | 326.8M | 62.4M | -134.5M | -802.3M | -2.19B | -2.34B | -2.68B | -1.71B | -2.79B |
Other Non-Cash Items | 1.55B | 2.46B | -3.4B | -444.2M | 1.71B | 1.63B | 2.24B | 3.88B | 3.35B | 1.71B |
Working Capital Changes | 3.2B | -2.38B | -1.69B | -747.4M | -1.01B | -800K | -3.06B | -5.38B | -8.09B | -6.39B |
Change in Receivables | -357M | -10.76B | -127.2M | -1.35B | -1.28B | -299.6M | -2.45B | -2.16B | -7B | 0 |
Change in Inventory | -253.9M | 7.8M | -258.7M | -533.4M | -235.9M | -599.7M | -1.43B | -2.51B | -4.67B | 0 |
Change in Payables | 916.3M | -284.5M | -477.7M | 1.27B | -1.01B | 1.33B | 4.27B | 2.61B | 10.19B | 0 |
Cash from Investing | -3.78B | 1.91B | -8.08B | -2.26B | -2.87B | -3.76B | -7.15B | -9.3B | -10.97B | -11.54B |
Capital Expenditures | -2.16B | -1.21B | -1.35B | -2.03B | -1.31B | -1.85B | -3.45B | -5.06B | -7.84B | -8.66B |
CapEx % of Revenue | 10.83% | 5.63% | 6.06% | 8.27% | 4.63% | 6.5% | 10.1% | 11.23% | 12.03% | 11.98% |
Acquisitions | -882.1M | 0 | -6.94B | -849.3M | -747.4M | -327.2M | -1.04B | -947.7M | -661M | -1.72B |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -175.1M | -2B | -248.7M | 102.8M | -644.3M | -1.34B | -2.53B | -3.04B | -2.79B | -1.31B |
Cash from Financing | 142.6M | -5.9B | -2.32B | -3.14B | -4.13B | -5.41B | 3.5B | 1.23B | -2.21B | -7.06B |
Debt Issued (Net) | 3B | -729.3M | 4.69B | 291.6M | 501.4M | -62M | 8.65B | 8.9B | 8.05B | 4.46B |
Equity Issued (Net) | -299.8M | -2.49B | -4.4B | -500M | -1.25B | -1.5B | -750M | -2.5B | -4.11B | -5.26B |
Dividends Paid | -2.19B | -2.31B | -2.41B | -2.69B | -3.09B | -3.54B | -4.07B | -4.68B | -5.38B | -5.59B |
Share Repurchases | -299.8M | -4.15B | -4.4B | -500M | -1.25B | -1.5B | -750M | -2.5B | -4.11B | -5.26B |
Other Financing | -364.4M | -372.8M | -200.1M | -241.6M | -295.9M | -308.9M | -335M | -490.6M | -772M | -676.7M |
Net Change in Cash | 1.95B▲ 0% | 1.46B▼ 25.2% | -5.66B▼ 487.2% | 1.32B▲ 123.3% | 161.4M▼ 87.8% | -1.75B▼ 1185.2% | 751.6M▲ 142.9% | 449.8M▼ 40.2% | 4B▲ 789.3% | 2.19B▲ 0% |
Free Cash Flow | 3.45B▲ 0% | 2.51B▼ 27.4% | 3.48B▲ 39.0% | 4.47B▲ 28.3% | 5.39B▲ 20.5% | 4.6B▼ 14.6% | -3.15B▼ 168.5% | 414.3M▲ 113.1% | 8.97B▲ 2065.6% | 13.58B▲ 0% |
FCF Margin % | 17.28% | 11.66% | 15.61% | 18.22% | 19.02% | 16.12% | -9.24% | 0.92% | 13.77% | 18.8% |
FCF Growth % | -8.17% | -27.4% | 38.97% | 28.35% | 20.51% | -14.61% | -168.52% | 113.14% | 2065.58% | 1169.45% |
FCF per Share | 3.28 | 2.42 | 3.64 | 4.67 | 5.65 | 4.84 | -3.49 | 0.46 | 9.99 | 15.16 |
FCF Conversion (FCF/Net Income) | -27.51x | 1.71x | 0.58x | 1.05x | 1.32x | 1.21x | 0.81x | 0.83x | 0.81x | 0.54x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LLY Key Ratios
Eli Lilly and Company (LLY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -1.59% | 28.63% | 122.26% | 145.32% | 74.52% | 62.67% | 48.43% | 84.26% | 101.15% | 101.17% |
Return on Invested Capital (ROIC) | 16.52% | 27.67% | 29.94% | 30.97% | 29.03% | 27.52% | 27.79% | 33.69% | 41.82% | 40.98% |
Gross Margin | 77.73% | 78.22% | 78.85% | 77.66% | 74.18% | 76.77% | 79.25% | 81.31% | 83.79% | 83.51% |
Net Margin | -1.02% | 15.04% | 37.27% | 25.24% | 19.71% | 21.88% | 15.36% | 23.51% | 31.66% | 34.98% |
Debt / Equity | 1.17x | 0.94x | 5.86x | 2.85x | 1.84x | 1.51x | 2.32x | 2.36x | 1.60x | 1.39x |
Interest Coverage | 11.24x | 16.18x | 14.15x | 21.11x | 19.12x | 21.53x | 14.49x | 17.24x | 33.16x | 35.68x |
FCF Conversion | -27.51x | 1.71x | 0.58x | 1.05x | 1.32x | 1.21x | 0.81x | 0.83x | 0.81x | 0.54x |
Revenue Growth | -5.88% | 7.61% | 3.84% | 9.95% | 15.4% | 0.79% | 19.56% | 32% | 44.7% | 47.44% |
Related:LLY Dividend History·LLY Revenue History·LLY Price History·LLY P/E History·LLY Financial Ratios·LLY Institutional Holders
LLY SEC Filings & Documents
Eli Lilly and Company (LLY) SEC filings — annual & quarterly reports (10-K, 10-Q)
LLY Frequently Asked Questions
Eli Lilly and Company (LLY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Eli Lilly and Company (LLY) reported $72.25B in revenue for fiscal year 2025. This represents a 932% increase from $7.00B in 1996.
Eli Lilly and Company (LLY) grew revenue by 44.7% over the past year. This is strong growth.
Yes, Eli Lilly and Company (LLY) is profitable, generating $25.27B in net income for fiscal year 2025 (31.7% net margin).
Dividend & Returns
Yes, Eli Lilly and Company (LLY) pays a dividend with a yield of 0.55%. This makes it attractive for income-focused investors.
Eli Lilly and Company (LLY) has a return on equity (ROE) of 101.2%. This is excellent, indicating efficient use of shareholder capital.
Eli Lilly and Company (LLY) generated $13.58B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.